Noradrenergic Drug Market Size & Share, by Application (Hyperactivity Depressant, Control Aggression, High Blood Pressure); Distribution Channel (Hospital Pharmacy, Drug Stores, Online Pharmacies) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2023-2035

  • Report ID: 3817
  • Published Date: Apr 14, 2023
  • Report Format: PDF, PPT

Companies Dominating the Noradrenergic Drug Landscape

top-features-companies
    • Baxter International, Inc.
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Eli Lilly and Company
    • Novartis AG
    • Bayer AG
    • Sanofi-aventis Groupe
    • Abbott Laboratories
    • Johnson & Johnson Services, Inc.
    • Merck & Co., Inc.
    • Siemens Healthcare GmbH
    • Pfizer Inc.

Browse Key Market Insights with Data Illustration:

In-the-news

In The News

  • Baxter International, Inc. introduced premix Norepinephrine Bitartrate in 5% Dextrose Injection, which can be can be kept in automated dispensing cabinets at the point-of-care and has a shelf life of up to 21 months in the refrigerator or up to 90 days at room temperature in overwrap. Further, it is used to treat individuals with acute or emergent hypotension

  • Sanofi-aventis Groupe acquired Provention Bio, Inc., to add TZIELD, the first disease-modifying therapy for the postponement of Stage 3 type 1 diabetes, to the portfolio. Further, the drug TZIELD (teplizumab-mzwv) can be used to postpone the onset of Stage 3 type 1 diabetes (T1D) in adults and children with Stage 2 T1D who are at least 8 years old.

 

 


Author Credits:  Radhika Gupta, Shivam Bhutani


  • Report ID: 3817
  • Published Date: Apr 14, 2023
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

Growing prevalence of autism, and surging incidences of hypertension are the major factors driving the market growth.

The market is anticipated to attain a CAGR of 3% over the forecast period, i.e., 2023-2035.

Lack of awareness regarding mental health, and exorbitant initial expenditure are estimated to be the growth-hindering factors for the market expansion.

The market in the Asian Pacific region is projected to hold the largest market share by the end of 2035 and provide more business opportunities in the future.

The major players in the market are Eli Lilly and Company, Novartis AG, Bayer AG, Sanofi-aventis Groupe, Abbott Laboratories, Johnson & Johnson Services, Inc., Merck & Co., Inc., Siemens Healthcare GmbH, Pfizer Inc., and others.

The company profiles are selected based on the revenues generated from the product segment, the geographical presence of the company which determines the revenue generating capacity as well as the new products being launched into the market by the company.

The market is segmented by application, distribution channel, and by region.

The hyperactivity depressant segment is anticipated to garner the largest market size by the end of 2035 and display significant growth opportunities.
Inquiry Before Buying Request Free Sample
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying